Last reviewed 2026-04-23 · How we verify

AZD 1775

AZD1775 is a selective inhibitor of the Wee1 kinase, which plays a critical role in cell cycle regulation and DNA damage response.

AZD1775 is a selective inhibitor of the Wee1 kinase, which plays a critical role in cell cycle regulation and DNA damage response. Used for Advanced solid tumors.

At a glance

Mechanism of action

By inhibiting Wee1 kinase, AZD1775 prevents the phosphorylation of cyclin-dependent kinases, leading to cell cycle arrest and apoptosis in cancer cells with compromised DNA repair mechanisms.

Approved indications

• Advanced solid tumors

Common side effects

• Thrombocytopenia
• Neutropenia
• Anemia

Key clinical trials

• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (PHASE2)
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
• Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours (PHASE1)
• AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer (PHASE2)
• Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (PHASE2)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (PHASE1)
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
• AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.